IQVIA Holdings Inc Asset Resilience Ratio
IQVIA Holdings Inc asset resilience ratio. IQVIA Holdings Inc (IQV) has an Asset Resilience Ratio of 0.57% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See IQVIA Holdings Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of IQVIA Holdings Inc (2011–2025)
Asset resilience ratio of IQVIA Holdings Inc from 2011 to 2025. This chart shows how IQVIA Holdings Inc's Asset Resilience Ratio has changed over time. Read IQVIA Holdings Inc (IQV) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down IQVIA Holdings Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see IQV current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $171.00 Million | 0.57% |
| Total Liquid Assets | $171.00 Million | 0.57% |
Asset Resilience Insights
- Limited Liquidity: IQVIA Holdings Inc maintains only 0.57% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
IQVIA Holdings Inc Industry Peers by Asset Resilience Ratio
Compare IQVIA Holdings Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
Wuhan Thalys Med Tech Co Ltd
SHG:603716 |
Diagnostics & Research | 0.16% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
Shanghai Rendu Biotechnology Co. Ltd. A
SHG:688193 |
Diagnostics & Research | 70.50% |
|
Krsnaa Diagnostics Limited
NSE:KRSNAA |
Diagnostics & Research | 9.90% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
IQVIA Holdings Inc Asset Resilience Ratio by Year (2011–2025)
IQVIA Holdings Inc asset resilience ratio by year from 2011 to 2025. The table below shows the annual Asset Resilience Ratio data for IQVIA Holdings Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 7.15% | $2.14 Billion | $29.94 Billion | +0.30pp |
| 2024-12-31 | 6.85% | $1.84 Billion | $26.90 Billion | +1.24pp |
| 2023-12-31 | 5.61% | $1.50 Billion | $26.68 Billion | +0.44pp |
| 2022-12-31 | 5.17% | $1.31 Billion | $25.34 Billion | -0.82pp |
| 2021-12-31 | 5.98% | $1.48 Billion | $24.69 Billion | -1.76pp |
| 2020-12-31 | 7.74% | $1.90 Billion | $24.56 Billion | +3.88pp |
| 2019-12-31 | 3.87% | $899.00 Million | $23.25 Billion | -0.29pp |
| 2018-12-31 | 4.16% | $938.00 Million | $22.55 Billion | -0.26pp |
| 2017-12-31 | 4.42% | $1.00 Billion | $22.74 Billion | -1.42pp |
| 2016-12-31 | 5.84% | $1.24 Billion | $21.21 Billion | +6.68pp |
| 2015-12-31 | -0.84% | $-32.91 Million | $3.93 Billion | +0.21pp |
| 2014-12-31 | -1.04% | $-34.50 Million | $3.31 Billion | +0.27pp |
| 2013-12-31 | -1.32% | $-40.35 Million | $3.07 Billion | +0.12pp |
| 2012-12-31 | -1.44% | $-35.95 Million | $2.50 Billion | -0.49pp |
| 2011-12-31 | -0.95% | $-22.11 Million | $2.32 Billion | -- |
About IQVIA Holdings Inc
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment of… Read more